文献速递银屑病与炎症性皮肤病

比美吉珠单抗治疗中重度银屑病的心理健康结局:2/3期随机试验分析

Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials.
PubMed 文献 · J Am Acad Dermatol · 2024-03-04

该分析基于9项比美吉珠单抗治疗中重度斑块状银屑病的2/3期临床试验,主动监测神经精神事件,采用电子哥伦比亚自杀严重程度评定量表(eC-SSRS)和患者健康问卷-9(PHQ-9)评估。在7166患者年的暴露期间,裁定自杀意念和行为(SIB)发生率为0.13/100患者年,第16周比美吉珠单抗组92.9% vs 安慰剂组81.1%无/轻微抑郁。结论认为比美吉珠单抗长期裁定SIB率低,与一般银屑病人群及抗IL-17A/抗IL-23治疗患者范围相当。

要点

  • 比美吉珠单抗长期裁定SIB发生率为0.13/100患者年,处于银屑病人群报告范围内。
  • 第16周无/轻微抑郁比例比美吉珠单抗组92.9%,安慰剂组81.1%。
  • 新发eC-SSRS阳性应答和平均PHQ-9评分在比美吉珠单抗组均较低。

核心结论

  • 比美吉珠单抗治疗中重度银屑病的长期裁定SIB率低,未超出一般银屑病人群及抗IL-17A/抗IL-23治疗患者的报告范围。

研究设计与样本

  • 对9项比美吉珠单抗治疗银屑病的2/3期临床试验进行心理健康变化主动监测,包括神经精神事件。
  • 使用患者自报的电子哥伦比亚自杀严重程度评定量表(eC-SSRS)评估SIB,患者健康问卷-9(PHQ-9)评估抑郁,由独立神经精神裁定委员会监督。

主要发现

  • 整个7166患者年的比美吉珠单抗暴露期间,裁定SIB率为0.13/100患者年。
  • 一般银屑病人群和接受抗IL-17A/抗IL-23治疗患者的SIB范围分别为0.09至0.54/100患者年和0.09至0.19/100患者年。
  • 第16周时,比美吉珠单抗组92.9% vs 安慰剂组81.1%的患者无/轻微抑郁。
  • 比美吉珠单抗治疗患者中新发eC-SSRS阳性应答和平均PHQ-9评分均较低。

关键数值与推荐

  • 裁定SIB率:0.13/100患者年(比美吉珠单抗暴露7166患者年)。
  • 第16周无/轻微抑郁比例:比美吉珠单抗组92.9%,安慰剂组81.1%。
  • 一般银屑病人群SIB范围:0.09至0.54/100患者年;抗IL-17A/抗IL-23治疗患者SIB范围:0.09至0.19/100患者年。

临床怎么用

  • 临床使用比美吉珠单抗治疗中重度银屑病时,可参考本研究的低SIB和抑郁监测数据。
  • 治疗期间仍需按常规进行心理健康筛查和监测,尤其对有相关病史的患者。

局限性

  • 研究排除了有明显/严重预设SIB/抑郁病史的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with psoriasis have increased risk of suicidal ideation and behavior (SIB) and depression. Bimekizumab, a biologic that inhibits interleukin (IL)-17A and IL-17F, received Food and Drug Administration approval in 2023 for moderate to severe plaque psoriasis, following 2021 European Medicines Agency approval. OBJECTIVE: To report SIB and depression in patients with moderate to severe psoriasis treated in bimekizumab clinical trials. METHODS: Mental health changes, including neuropsychiatric events, were actively monitored across 9 bimekizumab clinical trials in psoriasis phase 2/3 trials. The patient-reported electronic Columbia-Suicide Severity Rating Scale (measuring SIB) and Patient Health Questionnaire-9 (measuring depression) were administered, monitored by an independent Neuropsychiatric Adjudication Committee. RESULTS: Throughout 7166 patient-years (PY) of bimekizumab exposure, the adjudicated SIB rate was 0.13/100PY; SIB ranges for the general psoriasis population and patients receiving anti-IL-17A/anti-IL-23 therapies are 0.09 to 0.54/100PY and 0.09 to 0.19/100PY, respectively. At week 16, 92.9% vs 81.1% of bimekizumab- vs placebo-treated patients had no/minimal depression. Newonset positive electronic Columbia-Suicide Severity Rating Scale responses and mean Patient Health Questionnaire-9 scores were low for bimekizumab-treated patients. LIMITATIONS: Patient exclusion for significant/severe prespecified SIB/depression history. CONCLUSION: The long-term adjudicated SIB rate with bimekizumab was low and within ranges reported in the general psoriasis patient population and psoriasis patients treated with anti-IL-17A/anti-IL-23 biologics. Screening/monitoring questionnaires reported low SIB and depression levels.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Blauvelt A, Armstrong A, Merola JF, et al. Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials. J Am Acad Dermatol. 2024. PMID: 38447700. doi:10.1016/j.jaad.2024.02.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。